Advances in microbial mevalonolactone production: from fermentative mevalonate accumulation to downstream lactonization

Engineering Microbiology Pub Date : 2026-03-01 Epub Date: 2025-12-24 DOI:10.1016/j.engmic.2025.100257
Hao Tang , Lihong Yin , Yiwen Jiang , Teng Xu , Ting Xue , Meimei Fu , Jianghao Chen , Jinshan Guo
{"title":"Advances in microbial mevalonolactone production: from fermentative mevalonate accumulation to downstream lactonization","authors":"Hao Tang ,&nbsp;Lihong Yin ,&nbsp;Yiwen Jiang ,&nbsp;Teng Xu ,&nbsp;Ting Xue ,&nbsp;Meimei Fu ,&nbsp;Jianghao Chen ,&nbsp;Jinshan Guo","doi":"10.1016/j.engmic.2025.100257","DOIUrl":null,"url":null,"abstract":"<div><div>Mevalonolactone (MVAL) is a high-value feedstock for the cosmetic industry, with (<em>R</em>)-(-)-MVAL as the sole bioactive enantiomer. Chemical synthesis, which is the traditional method for MVAL production, is hindered by cumbersome procedures, low chiral purity, and sensitivity to humidity. Microbial fermentation <em>via</em> fermentative mevalonate (MVA) accumulation followed by <em>in vitro</em> acid-catalyzed lactonization has emerged as a promising alternative for producing optically pure (<em>R</em>)-(-)-MVAL. Strategies for MVA overproduction in microbial systems are reviewed, including the selection of chassis strains and enzymes for the MVA biosynthetic pathway, metabolic engineering approaches for strain improvement, optimization of fermentation processes, and downstream processes for MVA-to-MVAL lactonization. Finally, prospects for advancing microbial MVAL production are discussed.</div></div>","PeriodicalId":100478,"journal":{"name":"Engineering Microbiology","volume":"6 1","pages":"Article 100257"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Engineering Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667370325000712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Mevalonolactone (MVAL) is a high-value feedstock for the cosmetic industry, with (R)-(-)-MVAL as the sole bioactive enantiomer. Chemical synthesis, which is the traditional method for MVAL production, is hindered by cumbersome procedures, low chiral purity, and sensitivity to humidity. Microbial fermentation via fermentative mevalonate (MVA) accumulation followed by in vitro acid-catalyzed lactonization has emerged as a promising alternative for producing optically pure (R)-(-)-MVAL. Strategies for MVA overproduction in microbial systems are reviewed, including the selection of chassis strains and enzymes for the MVA biosynthetic pathway, metabolic engineering approaches for strain improvement, optimization of fermentation processes, and downstream processes for MVA-to-MVAL lactonization. Finally, prospects for advancing microbial MVAL production are discussed.

Abstract Image

微生物甲羟戊酸内酯生产的进展:从发酵甲羟戊酸积累到下游内酯化
Mevalonolactone (MVAL)是化妆品行业的高价值原料,(R)-(-)-MVAL是唯一具有生物活性的对映体。化学合成是生产MVAL的传统方法,但由于程序繁琐、手性纯度低、对湿度敏感等问题,阻碍了MVAL的生产。微生物发酵通过发酵甲羟戊酸(MVA)积累,然后体外酸催化内酯化已成为生产光学纯(R)-(-)- mval的一种有前途的替代方法。综述了微生物系统中MVA过量生产的策略,包括MVA生物合成途径的基础菌株和酶的选择,菌株改良的代谢工程方法,发酵过程的优化以及MVA到mval内酯化的下游工艺。最后,对推进微生物MVAL生产的前景进行了展望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书